Treating iron overload in patients with non-transfusion-dependent thalassemia

被引:69
作者
Taher, Ali T. [1 ]
Viprakasit, Vip [2 ,3 ]
Musallam, Khaled M. [1 ,4 ]
Cappellini, M. Domenica [4 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Pediat, Bangkok 10700, Thailand
[3] Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Thalassemia Ctr, Bangkok 10700, Thailand
[4] Univ Milan, Ca Granda Fdn IRCCS, Dept Med & Med Special, Milan, Italy
关键词
MAGNETIC-RESONANCE EVALUATION; BETA-THALASSEMIA; HEPATIC IRON; CHELATION-THERAPY; SERUM FERRITIN; HEPATOCELLULAR-CARCINOMA; SPLENECTOMIZED ADULTS; PEPTIDE HEPCIDIN; H DISEASE; LIVER;
D O I
10.1002/ajh.23405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite receiving no or only occasional blood transfusions, patients with non-transfusion-dependent thalassemia (NTDT) have increased intestinal iron absorption and can accumulate iron to levels comparable with transfusion-dependent patients. This iron accumulation occurs more slowly in NTDT patients compared to transfusion-dependent thalassemia patients, and complications do not arise until later in life. It remains crucial for these patients' health to monitor and appropriately treat their iron burden. Based on recent data, including a randomized clinical trial on iron chelation in NTDT, a simple iron chelation treatment algorithm is presented to assist physicians with monitoring iron burden and initiating chelation therapy in this group of patients. Am. J. Hematol. 88: 409-415, 2013. (C) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:409 / 415
页数:7
相关论文
共 96 条
[1]   Thalassernia heart disease - A comparative evaluation of Thalassemia major and Thalassemia intermedia [J].
Aessopos, A ;
Farmakis, D ;
Deftereos, S ;
Tsironi, A ;
Tassiopoulos, S ;
Moyssakis, I ;
Karagiorga, M .
CHEST, 2005, 127 (05) :1523-1530
[2]   Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients [J].
Akrawinthawong, Krittapoom ;
Chaowalit, Nithima ;
Chatuparisuth, Thanasaporn ;
Siritanaratkul, Noppadol .
HEMATOLOGY, 2011, 16 (02) :113-122
[3]   UNEVEN HEPATIC IRON AND PHOSPHORUS DISTRIBUTION IN BETA-THALASSEMIA [J].
AMBU, R ;
CRISPONI, G ;
SCIOT, R ;
VANEYKEN, P ;
PARODO, G ;
IANNELLI, S ;
MARONGIU, F ;
SILVAGNI, R ;
NURCHI, V ;
COSTA, V ;
FAA, G ;
DESMET, VJ .
JOURNAL OF HEPATOLOGY, 1995, 23 (05) :544-549
[4]   Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload [J].
Anderson, LJ ;
Holden, S ;
Davis, B ;
Prescott, E ;
Charrier, CC ;
Bunce, NH ;
Firmin, DN ;
Wonke, B ;
Porter, J ;
Walker, JM ;
Pennell, DJ .
EUROPEAN HEART JOURNAL, 2001, 22 (23) :2171-2179
[5]  
[Anonymous], GUID CLIN MAN THAL
[6]  
[Anonymous], 2001, THALASSAEMIA SYNDROM
[7]   Organ-specific hemosiderosis and functional correlation in Chinese patients with thalassemia intermedia and hemoglobin H disease [J].
Au, W. Y. ;
Lam, W. W. M. ;
Chu, W. W. C. ;
Tam, S. ;
Wong, W. K. ;
Lau, J. ;
Yeung, Y. M. ;
Liu, H. S. Y. ;
Liang, R. .
ANNALS OF HEMATOLOGY, 2009, 88 (10) :947-950
[8]   HEPATOCELLULAR-CARCINOMA IN THALASSEMIA MAJOR [J].
BORGNAPIGNATTI, C ;
DESTEFANO, P ;
SESSA, F ;
AVATO, F .
MEDICAL AND PEDIATRIC ONCOLOGY, 1986, 14 (06) :327-328
[9]   HEPATIC IRON STORES AND PLASMA FERRITIN CONCENTRATION IN PATIENTS WITH SICKLE-CELL-ANEMIA AND THALASSEMIA MAJOR [J].
BRITTENHAM, GM ;
COHEN, AR ;
MCLAREN, CE ;
MARTIN, MB ;
GRIFFITH, PM ;
NIENHUIS, AW ;
YOUNG, NS ;
ALLEN, CJ ;
FARRELL, DE ;
HARRIS, JW .
AMERICAN JOURNAL OF HEMATOLOGY, 1993, 42 (01) :81-85
[10]  
BUSH VJ, 1995, CLIN CHEM, V41, P284